Exchange: NASDAQ·Updated 10:33 AM EDT
News
all
press releases
Curis Doses First Five Patients in TakeAim CLL Study
Curis Doses First Five Patients in TakeAim CLL Study Curis Doses First Five Patients in TakeAim CLL Study PR Newswire LEXINGTON, Mass., July 30, 2026 LEXINGTON, Mass., July 30, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib...
PR Newswire
More News
Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus
Curis gained attention after positive emavusertib data as analyst raised its price target to $43 and highlighted upcoming trial catalysts.read more...
Benzinga
Curis Strengthens Oncology Pipeline Outlook With Strong TakeAim Lymphoma Response Rates
Curis shares positive updated clinical data for emavusertib and increases its year-end guidance for the TakeAim CLL study.read more...
Benzinga
Curis Announces Positive Emavusertib Update
Curis Announces Positive Emavusertib Update Curis Announces Positive Emavusertib Update PR Newswire LEXINGTON, Mass., July 22, 2026 Updated Clinical Data in PCNSLIncreased Guidance on Year-End Data in CLLCompany to Host Webcast at 8:30 a.m. ETLEXINGTON, Mass., July 22, 2026 /PRNewswire/ -- Curis...
PR Newswire
Why Q32 Bio Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
Gainers: Q32 Bio up 29.6%, Mint up 75.8%, Fast Track up 58.2%, eLong up 33.4%, Sobr Safe up 29.2%, Eshallgo up 20.3%, Curis up 10.9%, Sky Quarry up 10.6%, Accuray up 9.5%, Bitzero up 5.5%. Losers: Global Mofy down 25.3%, Jiuzi down 22.1%, Julong down 21.4%, Haoxi down 20.4%, Sadot down 20.4%.read...
Benzinga
Curis Consents First Six Patients in TakeAim CLL Study
Curis Consents First Six Patients in TakeAim CLL Study Curis Consents First Six Patients in TakeAim CLL Study PR Newswire LEXINGTON, Mass., July 6, 2026 LEXINGTON, Mass., July 6, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib...
PR Newswire
Why Did Curis (CRIS) Stock Soar After Hours?
Curis, Inc. shares surged 8.51% after the bell after the company confirmed its approved reverse stock split will take effect on Thursday.read more...
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Curis (NASDAQ:CRIS) stock rose 9.0% to $0.46 during Wednesday's after-market session. The company's market cap stands at $20.3 million. Humacyte (NASDAQ:HUMA) shares moved upwards by 5.45% to $0.71.read more...
Benzinga
Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split
Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of...
PR Newswire
Curis Reports Q1 2026 Results: Full Earnings Call Transcript
read more...
Benzinga

Advertisement|Remove ads.